Publications

Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values. by Pfaller MA, Chaturvedi V, Diekema DJ, Ghannoum MA, Holliday NM, Killian SB, Knapp CC, Messer SA, Miskou A and Ramani R published in Diagn. Microbiol. Infect. Dis. 2012; 73 (4): 365-368

Candida glabrata: Multidrug resistance and increased virulence in a major opportunistic fungal pathogen. by Pfaller MA, Castanheira M, Lockhart SR and Jones RN published in Curr. Fungal Infect. Rep. 2012; 6 (3): 154-164

Advances in antifungal susceptibility testing of Candida, 2010-2012. by Pfaller MA, Castanheira M and Jones RN published in Curr. Fungal Infect. Rep. 2012; 6 (3): 141-153

Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. by Pfaller MA and Diekema DJ published in J. Clin. Microbiol. 2012; 50 (9): 2846-2856

Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance program. by Pfaller MA, Woosley LN, Messer SA, Jones RN and Castanheira M published in Mycopathologia 2012; 174 (4): 259-271

Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial. by Farrell DJ, Turner LL, Castanheira M and Jones RN published in Diagn. Microbiol. Infect. Dis. 2012; 74 (1): 73-74

Activity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strains. by Biedenbach DJ, Turner LL, Jones RN and Farrell DJ published in Diagn. Microbiol. Infect. Dis. 2012; 74 (2): 204-206

Resistance trends in Gram-negative bacteria: Surveillance results from two Mexican hospitals, 2005-2010 by Morfin-Otero R, Tinoco-Favila JC, Sader HS, Salcido-Gutierrez L, Perez-Gomez HR, Gonzalez-Diaz E, Petersen L and Rodriguez-Noriega E published in BMC Res. Notes 2012; 5: 277

LEADER Surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers) by Flamm RK, Farrell DJ, Mendes RE, Ross JE, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2012; 4 (1): 54-61

Molecular epidemiology of Staphylococcus epidermidis clinical isolates from USA hospitals. by Mendes RE, Deshpande LM, Costello A and Farrell DJ published in Antimicrob. Agents Chemother. 2012; 56 (9): 4656-4661

Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: Results from CAPITAL Surveillance 2010. by Queenan AM, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, Peterson J and Davies TA published in Diagn. Microbiol. Infect. Dis. 2012; 73 (3): 267-270

Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis by Diaz L, Kiratisin P, Mendes R, Panesso D, Singh KV and Arias CA published in Antimicrob. Agents Chemother. 2012; 56 (7): 3917-3922

The PATH (Prospective Antifungal Therapy) alliance registry and invasive fungal infections: Update 2012. by Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP and Horn D published in Diagn. Microbiol. Infect. Dis. 2012; 73 (4): 293-300

Caspofungin Etest susceptibility testing of Candida species: Risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. by Arendrup MC and Pfaller MA published in Antimicrob. Agents Chemother. 2012; 56 (7): 3965-3968

Ceftaroline applications for therapy in the United States by Corey GR and Jones RN published in Clin. Infect. Dis. 2012; 55 (Suppl 3): S171-S172

Ceftaroline potency among 9 US census regions: Report from the 2010 AWARE program. by Flamm RK, Sader HS, Farrell DJ and Jones RN published in Clin. Infect. Dis. 2012; 55 (Suppl 3): S194-S205

AWARE ceftaroline surveillance program (2008-2010); Trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. by Pfaller MA, Farrell DJ, Sader HS and Jones RN published in Clin. Infect Dis. 2012; 55 (Suppl 3): S187-S193

Activity of ceftaroline-avibactam tested against gram-negative organism populations, including strains expressing one or more beta-lactamases and methicillin-resistant Staphylococcus aureus carrying various SCCmec types. by Castanheira M, Sader HS, Farrell DJ, Mendes RE and Jones RN published in Antimicrob. Agents Chemother. 2012; 56 (9): 4779-4785

Activity analyses of staphylococcal isolates from pediatric, adult and elderly patients; AWARE ceftaroline surveillance program. by Sader HS, Flamm RK, Farrell DJ and Jones RN published in Clin. Infect. Dis. 2012; 55 (Suppl 3): S181-S186

In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: A review of published studies and the AWARE surveillance program (2008-2010). by Farrell DJ, Castanheira M, Mendes RE, Sader HS and Jones RN published in Clin. Infect. Dis. 2012; 55 (Suppl 3): S206-S214

Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents. by Mendes RE, Sader HS, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2012; 56 (7): 3999-4004

Oritavancin microbiologic features and activity results from the surveillance program in the United States. by Mendes RE, Farrell DJ, Sader HS and Jones RN published in Clin. Infect. Dis. 2012; 54 (Suppl 3): S203-S213

Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. by Mendes RE, Tsakris A, Sader HS, Jones RN, Biek D, McGhee P, Appelbaum PC and Kosowska-Shick K published in J. Antimicrob. Chemother. 2012; 67 (6): 1321-1324

Comparison of Escherichia coli ST131 pulsotypes, by epidemiologic traits, 1967-2009. by Johnson JR, Nicolas-Chanoine MH, DebRoy C, Castanheira M, Robicsek A, Hansen G, Weissman S, Urban C, Platell J, Trott D, Zhanel G, Clabots C, Johnston BD and Kuskowski MA published in Emerg. Infect. Dis. 2012; 18 (4): 598-607

The changing epidemiology of healthcare-associated candidemia over three decades. by Diekema D, Arbefeville S, Boyken L, Kroeger J and Pfaller M published in Diagn. Microbio. Infect. Dis. 2012; 73 (1): 45-48

Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone. by Davies TA, Flamm RK and Lynch AS published in Int. J. Antimicrob. Agents. 2012; 39 (6): 534-538

Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia. by Biedenbach DJ, Farrell DJ, Flamm RK, Liverman LC, McIntyre G and Jones RN published in Int. J. Antimicrob. Agents. 2012; 39 (4): 321-325

Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections. by Arias CA, Mendes RE, Stilwell MG, Jones RN and Murray BE published in Clin. Infect. Dis. 2012; 54 (Suppl 3): S233-S238

Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs). by Sader HS, Paukner S, Ivezic-Schoenfeld Z, Biedenbach DJ, Schmitz FJ and Jones RN published in J. Antimicrob. Chemother. 2012; 67 (5): 1170-1175

Antimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative Staphylococcus. by Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2012; 73 (2): 212-214

Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. by Pfaller MA, Espinel-Ingroff A, Castanheira M, Cuenca-Estrella M, Diekema DJ, Fothergill A, Faller J, Ghannoum M, Jones RN, Lockhart SR, Ostrosky-Zeichner L and Pelaez T published in J. Clin. Microbiol. 2012; 50 (6): 2040-2046

Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. by Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA and Jones RN published in J. Clin. Microbiol. 2012; 50 (4): 1199-1203

Cryptococcus neoformans-Cryptococcus gattii species complex: An international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. by Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, Fothergill A, Fuller J, Hagen F, Govender N, Guarro J, Johnson E, Lass-Florl C, Lockhart SR, Martins MA, Meis JF, Melhem MS, Ostrosky-Zeichner L, and Turnidge J published in Antimicrob. Agents Chemother. 2012; 56 (6): 3107-3113

Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones. by Segreti J, Jones RN and Bertino JS published in J. Ocul. Pharmacol. Ther. 2012; 28 (1): 3-11

Summary of ceftaroline activity against pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program. by Flamm RK, Sader HS, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2012; 56 (6): 2933-2940

Antifungal drug resistance: Mechanisms, epidemiology, and consequences for treatment. by Pfaller MA published in Am. J. Med. 2012; 125 (1 Suppl): S3-S13

Oritavancin activity against vancomycin-susceptible and vancomycin-resistant enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010. by Mendes RE, Woosley LN, Farrell DJ, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2012; 56 (3): 1639-1642

Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA hospitals (2007-2009). by Mendes RE, Sader HS, Farrell DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2012; 72 (1): 113-117

Pharmacodynamics of beta-lactamase inhibition by NXL104 in combination with ceftaroline, examining organisms with multiple types of beta-lactamases. by Louie A, Castanheira M, Liu W, Grasso C, Jones RN, Williams G, Critchley I, Thye D, Brown D, Vanscoy B, Kulawy R and Drusano GL published in Antimicrob. Agents Chemother. 2012; 56 (1): 258-270

Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. by Fernandez J, Abbanat D, Shang W, He W, Amsler K, Hastings J, Queenan AM, Melton JL, Barron AM, Flamm RK and Lynch AS published in Antimicrob. Agents Chemother. 2012; 56 (3): 1476-1484

Expansion of clonal complex 258 KPC-2-producing Klebsiella pneumoniae in Latin American hospitals: Report of the SENTRY antimicrobial surveillance program. by Castanheira M, Costello AJ, Deshpande LM and Jones RN published in Antimicrob. Agents Chemother. 2012; 56 (3): 1668-1669

Evaluation of quinolone resistance-determining region mutations and efflux pump expression in Neisseria meningitidis resistant to fluoroquinolones. by Castanheira M, Deshpande LM, Jones RN and Farrell DJ published in Diagn. Microbiol. Infect. Dis. 2012; 72 (3): 263-266

Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods. by Castanheira M, Duncanson FP, Diekema DJ, Guarro J, Jones RN and Pfaller MA published in Antimicrob. Agents Chemother. 2012; 56 (1): 352-357

Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against gram-positive organisms commonly associated with acute bacterial skin and skin structure infections. by Sader HS, Biedenbach DJ, Paukner S, Ivezic-Schoenfeld Z, Jones RN published in Antimicrob. Agents Chemother. 2012; 56 (3): 1619-1623

Antimicrobial Activity of Ceftaroline/NXL104 Tested Against Contemporary (2010) Clinical Isolates from USA Medical Centers, Lead author: Sader HS, presented at 49th annual Infectious Diseases Society of America (IDSA), October 20 – 23, 2011, Boston, MA

Antimicrobial Activity and Spectrum of the Novel Cephalosporin Ceftaroline Tested Against Bacterial Isolates Causing Skin and Skin Structure Infections in USA Medical Centers, Lead author: Sader HS, presented at 49th annual Infectious Diseases Society of America (IDSA), October 20 – 23, 2011, Boston, MA

Activity of JNJ-Q2 and Comparators against Genetically Defined MRSA Clones, Lead author: Farrell DJ, presented at 49th annual Infectious Diseases Society of America (IDSA), October 20 – 23, 2011, Boston, MA

Evaluation of Occurrence and Resistance Mechanisms of Pleuromutilins in Staphylococcus aureus Clinical Isolates: Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Mendes RE, presented at 49th annual Infectious Diseases Society of America (IDSA), October 20 – 23, 2011, Boston, MA

Activity of JNJ-Q2, a Novel Fluoroquinolone, Tested against Neisseria gonorrhoeae, Including Ciprofloxacin-Resistant Strains, Lead author: Farrell DJ, presented at 49th annual Infectious Diseases Society of America (IDSA), October 20 – 23, 2011, Boston, MA

Wild-Type MIC Distributions and Epidemiological Cutoff Values for Fluconazole, Posaconazole and Voriconazole versus Cryptococcus neoformans as Determined by 72 hour CLSI Broth Microdilution Method, Lead author: Pfaller MA, presented at 49th annual Infectious Diseases Society of America (IDSA), October 20 – 23, 2011, Boston, MA